
The PSICHE study aimed to investigate the detection rate and outcomes of biochemical relapse treatment using 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) in patients with prostate-specific antigen (PSA) levels between 0.2 and 1 ng/mL. A treatment algorithm tailored to the imaging results was followed, including salvage radiotherapy, stereotactic body radiotherapy, and androgen deprivation therapy. Out of 100 enrolled patients, negative/positive results were observed in the prostate bed for 72 patients, while the pelvic nodal or extrapelvic metastatic disease was detected in 23 and 5 patients, respectively. The study demonstrated that certain factors like high-risk features, advanced stage, and high ISUP score were associated with a higher rate of positive PSMA PET/CT results. The PSICHE trial provides a valuable framework for integrating modern imaging and metastasis-directed therapy in a clinical setting.
Like
Save
Share